NCT00097227 - Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

Cetuximab

"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."

DRUG

Carboplatin

(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.

DRUG

Paclitaxel

225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.

Trial Locations (20)

19141

ImClone Investigational Site, Philadelphia

19713

ImClone Investigational Site, Newark

21204

ImClone Investigational Site, Baltimore

23230

ImClone Investigational Site, Richmond

26506

ImClone Investigational Site, Morgantown

27599

ImClone Investigational Site, Chapel Hill

29209

ImClone Investigational Site, Columbia

30084

ImClone Investigational Site, Tucker

32804

ImClone Investigational Site, Orlando

33705

ImClone Investigational Site, St. Petersburg

37920

ImClone Investigational Site, Knoxville

40202

ImClone Investigational Site, Louisville

47804

ImClone Investigational Site, Terra Haute

48197

ImClone Investigational Site, Ypsilanti

76508

ImClone Investigational Site, Temple

77024

ImClone Investigational Site, Houston

90089

ImClone Investigational Site, Los Angeles

90404

ImClone Investigational Site, Santa Monica

98405

ImClone Investigational Site, Tacoma

07112

ImClone Investigational Site, Newark